Thomas Tedder

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Thomas Fletcher Tedder, Ph.D., (born May 14, 1956) is an American immunologist. He is best known for his work in the fields of B lymphocyte biology and regulation. He is currently the Alter E. Geller Professor for Research in Immunology at Duke University.[1]

Career[edit]

Tedder received his Ph.D. in molecular cell biology from the University of Alabama in 1984 and completed his postdoctoral training as a Research Fellow in Pathology at Harvard Medical School. He was a faculty member at Dana-Farber Cancer Institute and Harvard Medical School from 1985 to 1998 before joining Duke University in 1993 as its founding Chairman of Immunology.[2] Tedder studies the structure and function of B lymphocyte cell surface molecules that regulate B cell function, activation, and signal transduction. He currently has 401 total publications and 25 issued patents relating to B cells and their products, including CD19, CD20, CD22, CD83, and L-selectin.[3] He has founded three biotherapeutic companies, including Angelica Therapeutics, Cellective Therapeutics, and most recently, Cellective BioTherapy.[4]

References[edit]

  1. ^ Duke University profile
  2. ^ http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=8410861
  3. ^ http://angelicatherapeutics.com/founders.html
  4. ^ http://www.bizjournals.com/triangle/news/2015/06/12/fred-eshelman-invests-cellective-biotherapy-duke.html